Vest Financial LLC Has $7.13 Million Position in Eli Lilly and Company $LLY

Key Points

• Vest Financial LLC increased its stake in Eli Lilly and Company by 39.3%, holding 9,150 shares valued at approximately $7.13 million by the end of the last quarter.
• Institutional investors now own 82.53% of Eli Lilly's stock, indicating significant interest from large financial entities in the company.
• Eli Lilly reported $6.31 EPS for its latest quarter, beating estimates by 0.72, with revenues of $15.56 billion, marking a 37.6% year-over-year increase.

Vest Financial LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,150 shares of the company's stock after acquiring an additional 2,580 shares during the quarter. Vest Financial LLC's holdings in Eli Lilly and Company were worth $7,133,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after acquiring an additional 682,203 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth about $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LLY shares. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. HSBC increased their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. JPMorgan Chase & Co. reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Finally, Berenberg Bank reissued a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $948.06.

Eli Lilly and Company Stock Performance

LLY opened at $818.60 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The stock has a market cap of $774.77 billion, a price-to-earnings ratio of 53.50, a PEG ratio of 1.18 and a beta of 0.47. The business has a 50 day moving average of $743.43 and a 200-day moving average of $765.54. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm posted $3.92 earnings per share. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. Company insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.